CN121532183A - Kras g12s和g12c抑制剂 - Google Patents
Kras g12s和g12c抑制剂Info
- Publication number
- CN121532183A CN121532183A CN202480046678.5A CN202480046678A CN121532183A CN 121532183 A CN121532183 A CN 121532183A CN 202480046678 A CN202480046678 A CN 202480046678A CN 121532183 A CN121532183 A CN 121532183A
- Authority
- CN
- China
- Prior art keywords
- fluoro
- pyrido
- compound
- methoxy
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363466476P | 2023-05-15 | 2023-05-15 | |
| US63/466,476 | 2023-05-15 | ||
| US202463626329P | 2024-01-29 | 2024-01-29 | |
| US63/626,329 | 2024-01-29 | ||
| PCT/US2024/029427 WO2024238633A2 (fr) | 2023-05-15 | 2024-05-15 | Inhibiteurs de kras g12s et g12c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN121532183A true CN121532183A (zh) | 2026-02-13 |
Family
ID=93520267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202480046678.5A Pending CN121532183A (zh) | 2023-05-15 | 2024-05-15 | Kras g12s和g12c抑制剂 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4712961A2 (fr) |
| KR (1) | KR20260010430A (fr) |
| CN (1) | CN121532183A (fr) |
| WO (1) | WO2024238633A2 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| CN121605110A (zh) | 2023-06-06 | 2026-03-03 | 金橘生物科技公司 | 取代杂环化合物及其用途 |
| WO2025101776A1 (fr) * | 2023-11-08 | 2025-05-15 | Kumquat Biosciences Inc. | Hétérocycles et leurs utilisations |
| WO2025167948A1 (fr) * | 2024-02-06 | 2025-08-14 | 上海齐鲁制药研究中心有限公司 | Inhibiteur de kras macrocyclique à base de pyrimidine |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ras抑制劑 |
| WO2025255438A1 (fr) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras |
| WO2025265060A1 (fr) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Compositions thérapeutiques et procédés de gestion d'effets liés au traitement |
| WO2026006747A1 (fr) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026015796A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015790A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015801A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble liés à ras |
| WO2026015825A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas |
| WO2026035947A1 (fr) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Conjugués médicamenteux à induction par liaison covalente ciblant kras comprenant une charge utile de topo-isomérase |
| WO2026035945A1 (fr) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Conjugués médicamenteux induits par covalence ciblant kras et comprenant une charge utile de topoisomérase |
| WO2026050446A1 (fr) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026064527A1 (fr) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Conjugués médicamenteux à induction covalente ciblant kras comprenant une charge utile d'inhibiteur de tubuline |
| WO2026064520A1 (fr) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Conjugués médicamenteux à induction covalente ciblant kras et comprenant une charge utile inhibitrice de tubuline |
| WO2026072904A2 (fr) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions et méthodes de traitement du cancer du poumon |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022002465A (es) * | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| EP4291199A4 (fr) * | 2021-02-09 | 2025-06-18 | Kumquat Biosciences Inc. | Composés hétérocycliques et leurs utilisations |
| US20240166669A1 (en) * | 2021-03-05 | 2024-05-23 | Nikang Therapeutics, Inc. | Quinazoline amine derivatives as kras inhibitors |
| WO2022256459A1 (fr) * | 2021-06-01 | 2022-12-08 | Quanta Therapeutics, Inc. | Modulateurs de kras et leurs utilisations |
| JP2025527530A (ja) * | 2022-08-16 | 2025-08-22 | ブリストル-マイヤーズ スクイブ カンパニー | Kras阻害剤 |
-
2024
- 2024-05-15 CN CN202480046678.5A patent/CN121532183A/zh active Pending
- 2024-05-15 WO PCT/US2024/029427 patent/WO2024238633A2/fr not_active Ceased
- 2024-05-15 EP EP24807992.3A patent/EP4712961A2/fr active Pending
- 2024-05-15 KR KR1020257041395A patent/KR20260010430A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024238633A3 (fr) | 2025-05-15 |
| KR20260010430A (ko) | 2026-01-20 |
| EP4712961A2 (fr) | 2026-03-25 |
| WO2024238633A2 (fr) | 2024-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN121532183A (zh) | Kras g12s和g12c抑制剂 | |
| KR102861303B1 (ko) | Kras g12c 억제제 | |
| KR102862474B1 (ko) | Parp7 억제제로서의 피리다지논 | |
| CN112437772B (zh) | Bcl-2抑制剂 | |
| AU2022232523A1 (en) | Kras g12d inhibitors | |
| AU2018243691B2 (en) | Heterocyclic compound | |
| JP2025506408A (ja) | キナゾリンpan-KRas阻害剤 | |
| AU2021401232A9 (en) | Azaquinazoline pan-kras inhibitors | |
| CN119677748A (zh) | 氢吡啶并嘧啶泛KRas抑制剂 | |
| AU2017259436A1 (en) | Piperidines as menin inhibitors | |
| TW202409030A (zh) | 五元並六元含氮化物、其中間體、製備方法和應用 | |
| EP3681885B1 (fr) | Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300 | |
| CN116057061B (zh) | Usp7抑制剂 | |
| CN118660880A (zh) | 喹唑啉泛KRas抑制剂 | |
| CN121464131A (zh) | Mllt1和mllt3抑制剂化合物 | |
| WO2025255298A1 (fr) | Inhibiteurs de pkc-thêta, compositions et procédés d'utilisation | |
| WO2024220399A1 (fr) | Pyrazolotriazinecarbonitriles utiles en tant qu'inhibiteurs de kinase | |
| HK40031697B (en) | Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors | |
| HK40031697A (en) | Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication |